Update on ethambutol optic neuropathy

Frederick W. Fraunfelder, Alfredo A. Sadun, Terry Wood

Research output: Contribution to journalReview article

41 Scopus citations

Abstract

Ethambutol optic neuropathy is a well-recognised adverse ocular event in patients who receive ethambutol for the treatment of mycobacterial infections. Much has been published on this condition; however, understanding of patient outcomes and the mechanism by which ethambutol optic neuropathy occurs, as well as data published in textbooks and reference books, tend to lag behind what is currently known. The purpose of this article is to update the clinician on what is currently accepted in regards to the clinical presentation of ethambutol optic neuropathy and what type of eye care should be provided to patients treated with this medication. In addition, new treatment recommendations are suggested to assist clinicians in complying with currently accepted standards of care.

Original languageEnglish (US)
Pages (from-to)615-618
Number of pages4
JournalExpert Opinion on Drug Safety
Volume5
Issue number5
DOIs
StatePublished - Sep 1 2006

    Fingerprint

Keywords

  • Ethambutol optic neuropathy
  • Ocular toxicology
  • Optic neuropathy
  • Postmarketing surveillance

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Fraunfelder, F. W., Sadun, A. A., & Wood, T. (2006). Update on ethambutol optic neuropathy. Expert Opinion on Drug Safety, 5(5), 615-618. https://doi.org/10.1517/14740338.5.5.615